2023 Family Heart Advocacy Highlights
The Family Heart Foundation wouldn’t be where it is today without the help of our Family Heart community. The key to raising awareness is by getting the message out, [...]
Family Heart Foundation Public Comment for Screening for Lipid Disorders in Children and Adolescents
A Response to the US Preventive Service Task Force On January 24, 2023, the US Preventive Services Task Force (USPSTF) released their draft recommendation based on evidence of the benefits [...]
ICER Report on Treatments for High Cholesterol – Family Heart Foundation to Comment at Public Meeting February 5
The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted [...]
FDA Listening Session for HoFH
the Family Heart Foundation started 2021 off with an impactful Listening Session with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research Division of Diabetes, Lipid Disorders, and Obesity [...]
the Family Heart Foundation Advocating on Capitol Hill
On January 28, 2020, the Family Heart Foundation and some of our amazing community members and leaders, who are FH Advocates for Awareness, will go to Capitol Hill to [...]
Global Call To Action on Familial Hypercholesterolemia Aims to Improve Diagnosis and Treatment Worldwide
Family Heart Foundation, World Heart Federation, and International Coalition Collaborate to Tackle the Global Burden of Familial Hypercholesterolemiathe Family Heart Foundation and the World Heart Federation announced today a Global [...]
Activating the FH Global Community
Familial Hypercholesterolemia Global Impact In 1998, the World Health Organization (WHO) and several members of the international FH Community published the WHO Report on Familial Hypercholesterolemia (FH). This prescient document [...]
Action Alert: Getting the Lower List Price for PCSK9 inhibitors
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor? The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for [...]
Prioritizing Familial Hypercholesterolemia as Global Health Concern
Family Heart Foundation Driving Global Policy Collaborations with the World Heart Federation and International FH Community In December 2018, three Family Heart Foundation team members — Katherine Wilemon, [...]
Advancing FH Care at NHLBI Workshop on Implementation Science and FH
Katherine Wilemon, Founder and CEO, Cat Davis Ahmed, Vice President of Policy and Outreach, and several Family Heart Foundation board members participated in a workshop convened by the National [...]
